288 related articles for article (PubMed ID: 22128166)
1. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
Ohto U; Usui K; Ochi T; Yuki K; Satow Y; Shimizu T
J Biol Chem; 2012 Jan; 287(3):1801-12. PubMed ID: 22128166
[TBL] [Abstract][Full Text] [Related]
2. [Structural basis for β-galactosidase associated with lysosomal disease].
Shimizu T
Yakugaku Zasshi; 2013; 133(5):509-17. PubMed ID: 23649392
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of pharmacological chaperoning for human β-galactosidase.
Suzuki H; Ohto U; Higaki K; Mena-Barragán T; Aguilar-Moncayo M; Ortiz Mellet C; Nanba E; Garcia Fernandez JM; Suzuki Y; Shimizu T
J Biol Chem; 2014 May; 289(21):14560-8. PubMed ID: 24737316
[TBL] [Abstract][Full Text] [Related]
4. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
5. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.
Hinek A; Zhang S; Smith AC; Callahan JW
Am J Hum Genet; 2000 Jul; 67(1):23-36. PubMed ID: 10841810
[TBL] [Abstract][Full Text] [Related]
6. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.
Callahan JW
Biochim Biophys Acta; 1999 Oct; 1455(2-3):85-103. PubMed ID: 10571006
[TBL] [Abstract][Full Text] [Related]
9. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
[TBL] [Abstract][Full Text] [Related]
10. Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.
Okumiya T; Sakuraba H; Kase R; Sugiura T
Mol Genet Metab; 2003 Jan; 78(1):51-8. PubMed ID: 12559848
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B.
Przybilla MJ; Ou L; Tăbăran AF; Jiang X; Sidhu R; Kell PJ; Ory DS; O'Sullivan MG; Whitley CB
Mol Genet Metab; 2019 Feb; 126(2):139-150. PubMed ID: 30528226
[TBL] [Abstract][Full Text] [Related]
12. Processing of human beta-galactosidase in GM1-gangliosidosis and Morquio B syndrome.
Hoogeveen AT; Graham-Kawashima H; d'Azzo A; Galjaard H
J Biol Chem; 1984 Feb; 259(3):1974-7. PubMed ID: 6420416
[TBL] [Abstract][Full Text] [Related]
13. Structural bases of GM1 gangliosidosis and Morquio B disease.
Morita M; Saito S; Ikeda K; Ohno K; Sugawara K; Suzuki T; Togawa T; Sakuraba H
J Hum Genet; 2009 Sep; 54(9):510-5. PubMed ID: 19644515
[TBL] [Abstract][Full Text] [Related]
14. Processing of lysosomal beta-galactosidase. The C-terminal precursor fragment is an essential domain of the mature enzyme.
van der Spoel A; Bonten E; d'Azzo A
J Biol Chem; 2000 Apr; 275(14):10035-40. PubMed ID: 10744681
[TBL] [Abstract][Full Text] [Related]
15. GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
Hofer D; Paul K; Fantur K; Beck M; Bürger F; Caillaud C; Fumic K; Ledvinova J; Lugowska A; Michelakakis H; Radeva B; Ramaswami U; Plecko B; Paschke E
Hum Mutat; 2009 Aug; 30(8):1214-21. PubMed ID: 19472408
[TBL] [Abstract][Full Text] [Related]
16. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
Front S; Almeida S; Zoete V; Charollais-Thoenig J; Gallienne E; Marmy C; Pilloud V; Marti R; Wood T; Martin OR; Demotz S
Bioorg Med Chem; 2018 Nov; 26(20):5462-5469. PubMed ID: 30270003
[TBL] [Abstract][Full Text] [Related]
17. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings.
Caciotti A; Garman SC; Rivera-Colón Y; Procopio E; Catarzi S; Ferri L; Guido C; Martelli P; Parini R; Antuzzi D; Battini R; Sibilio M; Simonati A; Fontana E; Salviati A; Akinci G; Cereda C; Dionisi-Vici C; Deodato F; d'Amico A; d'Azzo A; Bertini E; Filocamo M; Scarpa M; di Rocco M; Tifft CJ; Ciani F; Gasperini S; Pasquini E; Guerrini R; Donati MA; Morrone A
Biochim Biophys Acta; 2011 Jul; 1812(7):782-90. PubMed ID: 21497194
[TBL] [Abstract][Full Text] [Related]
18. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
Fantur KM; Wrodnigg TM; Stütz AE; Pabst BM; Paschke E
J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
[TBL] [Abstract][Full Text] [Related]
19. Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.
Higaki K; Ninomiya H; Suzuki Y; Nanba E
Future Med Chem; 2013 Sep; 5(13):1551-8. PubMed ID: 24024947
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable β-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal β-galactosidase mutant R201C.
Thonhofer M; Weber P; Gonzalez Santana A; Tysoe C; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Carbohydr Res; 2016 Jun; 429():71-80. PubMed ID: 27063389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
